MASH (metabolic dysfunction-associated steatohepatitis) is a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis
Like GLP-1, amylin is thought to slow gastric emptying, reduce glucagon secretion, increase satiety and reduce appetite, and to be frank, I personally didnt do a deeper dive on Amylin because when Novo Nordisk presented CagriSema at the ADA conference they were sparse on the details beyond talking up synergy with GLP-1
Your body stores glucose as glycogen in your liver and muscles
Commonly reported side effects include nausea (2533%) , diarrhea (1823%) , and vomiting (813%) , mostly during the dose-escalation phase
Studies were approved by the Human Research Ethics Committee of the South Eastern Sydney Local Health District